DAFTAR PUSTAKA

Amaratungga C, Sreng S, Suon S, 2012. Artemisin resistant Plasmodium falciparum in Pursat province Western Cambodia: a parasit clearance study. *Lancet Infect Dis*. 12(11), p851-858.

Anderson TJ, Haubold B, Williams JT, 2000. Microsatellite markers refeal a spectrum of polpulation structures in the malaria parasite *Plasmodium falciparum*. Mol.Biol.Evol. 17, p1467-1482

Afonso, A., Hunt, P., Cheesman, S., Alves, A.C., Cunha, C.V., Do-rosario, V., Cravo, P., 2006. Malaria prasites can develop stable resistance to artemisinin but lack muations in candidate gene atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase)tctp, mdr1, and cg10. *Antimicrobial agent and chemotherapi,* 50(2), pp.480-9

Ariey F, Duchmain JB, Robert P, 2003. Metapopulation concepts applied to falciparum malaria and their in fact on the emergence and spread of cloroquine resistance. *Infect. Genet.Evol*.2. p185-192.

Ariey, F., Witkowsi, B., Amaratungg, C., Beighen J., Langlois, A.C., Khim N., Kim, S., Duru, V., Bouchler, C., 2014. A molecular marker of artemisinin resistant Plasmodium falciparum malaria. *Nature*, 505, pp50-55.

Ashley *et al.,* 2014. Spread of artemisinin resistant in Plasmodium falciparum malaria. *N Engl J Med,* 371, pp. 411-23

Bartolini A and Zammarci L, 2012. Clinical Aspects of Uncomplicated and Severe Malaria. Mediterr J Hematol Infect Dis, 4.

Bertaux, L., Quang, LH., Sinau, V., Thanh, NX., Parzy, D. 2009. New PfATP6 mutation found in Plasmodium falciparum isolates from Vitenam. *Antimicrobial agents and chemotherapy*, 53(10), pp 4570-1

Beshir, K., Sutherland, CJ., Merinopoulos, I., Durrani, N., Leslie, T., Rowland, M., Hallet, RL. 2010. Amodiaquine resistance in Plasmodium falciparum isolates from Vietnam, *Antimicrobial agents and chemotherapy*, 54(9), pp.3714-6

Bhattarai, A., Ali, A.S., Kachur, S.P., 2007. Impact of artemisinin-based combination therapy and insectised traeted nets in malaria burden in Zanzibar, *PLoS Med*, 4(11): e309.

Biggs, N.A., dan Brown, G.V., 2001. *Malaria dalam Principles and Practice of Clinical Parasitology*, Chichester, England: Jhon Willey and Sons, LTD.

Briand V, 2016. Prevalence of malaria in pregnancy in southern Laos: a cross-sectional survey. Malar J. 15(436)

Brunton, L., Parker, K., Blumenthal, D., Buxton, I. 2008. *Goodman and Gilman's Manual of Pharmacology and Therapeutics*. New York: Mac Graw Hill Medical.

Carrara VI, Zwang J, Ashley EA. 2009. Changes in the treatment responses to artesunate-mefloquine on the north western border of Thailand during 13 years of continous deployment. *Plos One.* 4. P4551.

Castellini MA, Buguliskis JS, Casta LJ, 2011. Malaria drug resistence is association with defective DNA missmatch repair. *Mol.Biochem.Parasitol.* 177, p143-147

Centers for Diseases Control and Prevention. 2012. Malaria. Available at : http;/www.dpd.cdc.gov/dpdx

Chatterjee M, Ganguly G, Saha P, Bankura B, Basu N, Das M *et al*, 2015. No polymorphism in Plasmodium falciparum K13 gene in clinical isolates from Kolkata India, *J of Path*, 7(4).

Cheng, Q., Cloonan, Ni., Fischer, K., Thomson, J., Weine, G., Lanzer, M., Saul, A., 1998. Stevor and rif are *Plasmodium falciparum* multi copy gene families with potentially encode variant antigen. *Molecular anf Biochemical Parasitology,* 97(1-2), pp.161-176.

Conrad, M.D., Bigira, V., Kapisi, J., Muhindo, M., Kamya, M.R., Havlir, D.V., Dorsey, G., Rosenthal, P.J., 2014. Polimorphisms in K13 and Falcipain-2 asoosciated with artemisinis resistance are not perevalent in *Plasmodium falciparum* isolated form Ugandan children. *Plos one*, 14(168)

Cui L, Yan G, Sattabongkot J, 2011. Malaria in greater mekong subregion : heterogeneity and complexity. *Acta Trop*. 121, p227-239

Dahlstrom, S., Viega M.I., Ferreira, P., 2008. Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falcuiparum (PfATP6) infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 8(3), pp340-5.

Dahlstrom, S. 2009. *Role PFATP6 and Pf MDR1 in Plasmodium falciparum Resistance to Antimalarial Drugs*. Stockholm: Karolinka Institute

Depkes RI, 2008. Pedoman Penatalaksanaan Kasus Malaria di Indonesia, Jakarta : Departemen Kesehatan Republik Indonesia.

Depkes RI. 2009. Profil Kesehatan Indonesia Tahun 2008. Jakarta : Departemen Kesehatan Republik Indonesia.

Depkes RI, 2015. Situasi Terkini Program Pengendalian Malaria di Indonesia Tahun 2014, Jakarta : Departemen Kesehatan Republik Indonesia.

Dinas Kesehatan Propinsi Lampung, 2015. Profil Kesehatan Lampung 2013. Lampung

Dinas Kesehatan Kabupaten Pesawaran, 2015. Evaluasi Program Pemberantasan Penyakit Menular (Malaria) Tahun 2014. Pesawaran, Lampung

Djimde, A., Doumbo O.K., Cortese, J.F., Kaeyento, K., 2001. A Molecular marker for chloroquine resistant falciparum malaria. *The New England Journal of Medicine,* 344(4). Pp.257-263.

Dondrop AM, Nosten F, Yi P, 2009. Artemisinin resistance in Plasmodium falciparum malaria. *N.Engl.J.Med.* 361, p455-467.

Dondrop, A.M., Ringwald P., 2009. Artemisinin resistant is clear and present danger, *Trends Parasitol*, 29, p359-360.

Garcia, L.S. dan Bruckner, D.A., 1997. *Diagnostic Medical Parasitology* 3rd ed., Washington DC: ASM Press

Gardner, M.J., Hall, N., Fung, E.,White, O., Berriman, M., Hyman, R.W., Carlton, J.M., Pain, A., Nelson, K.E., 2002. Genom sequence of the human malaria parasite *Plasmodium falciparum. Nature*, 419 (6906), pp.498-511.

Gehlawat VK, Arya V, Kausik JS, Gathwala G, 2013. Clinical spectrum and treatment outcome of severe malaria caused by Plasmodium vivax in 18 children from northern India. Pathohen and Global Heath. 107(4)

Golenser, J., Wagnine, JH., Krugliak, M. 2006. Current perspectives on mechanism of action of artemisinins. International journal of parasitology, 36(14), pp 1427-41

Hansky IA and Simberloffe D, 1997. *The metapopulation approach, its history, conceptual domain and application to conservation*. P5-26 *in* Hansky IA, and Gillpin ME, Eds. *Metapopulation biology : ecology, genetics, and evolution*. Academic Press. San Diego

Heelan, J.S dan Ingersoll, F.W., 2002. *Essential of Human Parasitology*, Albani (NY): Delmar Thomson Learning, Inc.

Humpreys, G.S., Merinopoulous, I., Ahmed, J., Whitty, C.J., Mutabingwa, T.K., Sutherland, C.J.,Hallet, R.L., 2007. Amodiaquine and arthemeter-lumefantrine selected distinct alleles of Plasmodium falciparum mdr1 gene in Tanzanian childeren treated for uncomplicated malaria. *Antimicrobial agents and chemotherapy*, 51(3). Pp.991-997

Ibrahim, ML., Khim, M., Adam, HH., Ariey, F., Duchemin, JB. 2009. Polymorphism of PfATPase in Niger. Detection of three new points. Malaria journal, 8, p 28.

Iwagami M, Rivera PT, Villacorte EA, 2009. Genetic diversity and population structure of *Plasmodium falciparum* in the Phillipines. Malar.J. 8, p96.

Isozumi R, Uemura H, Kimata I, Ichinose Y. Novel mutation in K13 propeller gene of artemisinin-resistant *Plasmodium falciparum. Emerg.Infect.Dis.*21(3)

Jambou, R., Martinelli, A., Pinto, J., Gribaldo, S., Legrand, E., Niang, M., Kim, N., Cravo. P. 2010. Geograpic structuring of Plasmodium falciparum sarco endoplasmic reticulum Ca2+ ATPase (PfSerca) gene diversity. PlosOne, 5(2), p.e9424.

Jung, M. Kim, H., Nam, KY., No, KT. 2005. Three dimensional structure of Plasmodium falciparum PfATP6ase and docking of artemisinin derivates to PfATP6. *Bioorganic and medical chemistry letters*, 15(12), p. 2994-7

Kamelia, M., 2010. *Studi polimorfisme gen Plasmodium falciparumchloroquine resistant transporter (PfCRT) dari penderita malaria di kotamadya Bandar Lampung dan Kabupaten Lampung Selatan, Propinsi Lampung*. Program Pasca Sarjana Universitas Gajah Mada.

Kannan, R., Kumar, K., Kukreti, S., Chauhan, VS. 2005. Reaction of artemisinin with haemoglobin : implications of antimalarial activity. *Biochem, J*, 418, pp.409-418

Katzung, B.G., 2006. *Katzung's Basic and Clinical Pharmacology*, San Fransisco: Mc Graw Hill Medical.

Kementrian Kesehatan Republik Indonesia, 2011a. Pedoman Penatalaksanaan Kasus Malaria di Indonesia. Jakarta: Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan.

Kementrian Kesehatan Republik Indonesia, 2011b. Profil Kesehatan Republik Indonesia 2010. Jakarta : Kementrian Kesehatan Republik Indonesia.

Kementrian Kesehatan Republik Indonesia, 2014. Profil Kesehatan Republik Indonesia 2013. Jakarta : Kementrian Kesehatan Republik Indonesia.

Kyaw MP, Nyunt MH, Chit K, 2013. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLos One. 8. (3)

Kyes, S.A., Rowe, J., Kriek, N., Newbold C.I., 1999. Riffins : A second family of clonally variant protein expressed on the surface of the red cell infected with Plasmodium falciparum. *Proc. Natl.Acad. Sci. USA*, 96(August 1999). Pp.9333-9338

Lim, P., Arker, AP., Khim, N, Ariey, F. 2009. PfMDR1 copy number and artemisinin derivatives combination therapi failure in Plasmodium falciparum in Cambodia. *Malaria journal*, 8, p.11

Lopes, D., Rungsihirunrat, K., Noguiera, F., Seougorn, A., Gill, J.P., Rosario, F.E., Cravo, P., 2002. Molecular characterization of drug resistant Plasmodium falciparum from *Thailand. Malaria Journa*l, 1(12). Pp.1-11.

Madamet, M.T., Fall, B., Benoit, C., Camara, C., Amalvict, R., Fall., M., Dione, P., Fall, KB., Nakoulima A., Diatta, B., Dieme, Y., Menard, D., Wade, B., Pradines, B., 2014. Limited polimorphisms in K13 gene ini Plasmodium falciparum isolates in Dakar, Senegal in 2012-2013, *Malaria Journal*, 13:472.

Markell, E.K., Voge, M. Dan john, D.T., 1986. *Medical Parasitology* 6th ed., PHiladelphia: WB Suanders Company

Mackinon MJ, 2005. Drug resistence model for malaria. *Acta Trop*. 94. P207-217

Menegon, M.,Sanella, AR., Majorie, G., Severini, C., 2008. Detection of novel points mutation in the Plasmodium falciparum ATPase6 candidate gene for resistance of artemisinins. *Parasitology International,* 57(2), pp.233-5.

Mendrofa, E. 2008. *Analisis spasial kasus malaria di Kecamatan Lahewa Kabupaten Nias Propinsi Sumatera Utara tahun 2006 dan 2007*. Program Studi Ilmu Kesehatan Masyarakat Pasca Sarjana Universitas Gajah Mada.

Mishra N, Parajapati SK, Kaitholia K, 2016. Survellance of artemisinin resistance in Plasmodium falciparum in India using the Kelch 13 molecular marker. *AAC. ASM.Org*. 59(9)

Mita T, and Tanabe K, 2012. Evolution of *Plasmodium falciparum* drug resistance for the developmentand containment of artemisinin resistance. *Jpn.J.Infect.dis.*65, p465-475

Mohon, A.N., Alam, M.S., Bayih, A.G., Folefoc, A., Shahinas, D., Haque R., Pillai, D.R., 2014. Mutation in Plasmodium falciparum K13 Propeller gene form Bangladesh (2009-2013). *Malaria Journal*, 13(431),

Monroe A, Asamoah O, Lam Y, 2015. Outdoor-sleeping and other night-time activities in northern Ghana: implications for residual transmission and malaria prevention. *Malaria Journal*, 13(431), 14, 35.

Natadisastra, D dan Rusmartini, T. 1999. *Bunga Rampai Protozoologi Kedokteran,* Edisi 2, Jatinangor Bandung: Bagian Parasitologi FK Unpad.

Noedl H, 2005. Artemisinin resistance : how can we find it?. *Trends Parasitol.* 21 p404-405

Noedl H., Se, Y., Schecer K., Smith B.L., Socheat D., Fukuda, MM., 2008. Evidence of artemisinin-resistant malaria in Western Cambodia. *N Engl J Med*, 359, pp.2619-2620.

O,Brien, C., Henrich, P.P., Passi, N., Fidock, D.A., 2011. Recent clinical and molecular insight into emerging artemisinin resistance in Plasmodium falciparum. *Cur Opin Infect Dis*, 24 (570)

Oackley MS, Gerald N, Mc Cutchan TF, Aravind L, Kumar S, 2011. Clinical and molecular aspects of malaria fever. Trends in Parasitol. 27(10), p442-449

Phillips A, Bassett,, Zeki, Newman S, 2009. Risk Factors for Severe Disease in Adults with Falciparum Malaria. *Clin.Infect.Dis*. 48, p871–878

Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, 1996. Effects of artemisinin derivatives on malaria transmissibility, Lancet, 347(9016), pp.1654-8.

Rang, Hp., Dale, M., Ritter, JM., Flower, RJ. 2007. *Rang and Dales Pharmacolofy 6th Ed*. Elsevier Inc

Rathod PK, McArlean T, Lee PC, 1997. Variantions in frequencies of drug resistance in *Plasmodium falciparum. Proc.Natl.Acad.Sci.USA,* p 9389-9393

Rodrigues, L., Henriques, G., Borges, ST., Hunt, P., Sanchezs, SP., Martinelli, A., Cravo, P., 2010. Experimental evolution of resistance to artemisinin combinanation therapy result of amplification mdr1 gene in rodentia malaria parasite, *PLoS One,* (July), pp.1-10

Roger WO, Sem R, Tero T, 2009. Failure of artesunate-mefloquine combination therapy for *Plasmodium falciparum* malaria in southern Cambodia. *Malar J*. 8. 10

Schwartz E, Sadetzki S, Murad H, Raveh D, 2001. Age as a Risk Factor for Severe *Plasmodium falciparum* Malaria in Nonimmune Patients. *Clin.Infect.Dis*. 33, p1774–1778

Sewa MY. (2013)Evaluasi Penggunaan Dihidroartemisinin+Piperakuin dan Primakuin pada pengobatan malaria falciparum tanpa komplikasi di kota Sorong Provinsi Papua Barat, (Thesis)

5
Sidhu, A.B.S., Valdermoss, S.G.,dan Fiddock, D.A., 2005. Pfmdr1 mutations contribute to quininie resistant and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum., 57.pp.913-926

Snow, R.W., Trape, J.F., Marsh, K., 2001. The past, present and future of childhood malaria mortality in Africa. *Trends Parasitol*, 17, pp.593-7

Sulistiowati, Z.D., 2011. *Analisis spasial kejadian malaria di Kecamatan Sosoh Buay Rayap Kabupaten Ogan Komering Ulu*, Program Studi Ilmu Kesehatan Masyarakat Pascasarjana Universitas Gajah Mada.

Suwandi JF, 2007. *Aktifitas antiplasmodium ekstrak daun sungkai (Peronema cannescens) : kajian aktifitas antiplasmodium in vitro dan in vivo, aktivitas oenghambatan polimerase hem dan aktifitas sitotoksik terhadap sel vero*. Ilmu Kedokteran Dasar dan Biomedik Fakultas Kedokteran UGM.

Suwandi, J.F., 2014. *Polimorfisme gen Pfmdr1 dan Pfatpase6 pada isolat Plasmodium dari penderita malaria falciparum di Kabupaten Pesawaran*. Program Pasca Sarjana Universitas Gajah Mada.

Tahar R, Ringwald P, Bosco L, 2009. Cameroon. XXVIII. In vitro activity of dihydroartemisinin againts clinical isolates of Plasmodium falciparum and sequence analysis of P.falciparum ATPase6 gene, 81(1), pp.13-19.

Trampuz A, Jerreb M, Muzlovic I, 2003. Clinical review : severe malaria. *Critical Care*. 7 (4)

Trevor AJ, Katzung BG, Master AB, 2002. Katzung and Trevor's Pharmacology. 6th ed. New York : Lange Medical Books

Verdreager J, 1986. Epidemiology of the emergence and spread of drug resistance falciparum malaria in Southeast Asia and Australasia. *J.Trop.Med.Hyg*. 89, p277-289

Waldman SA and Terzic A, 2009. Pharmacology and Therapeutics Principles to Practise. Philladelphia : Saunders Elseviers.

Warhurst, D.C., 2001. Amolecular marker for chloroquine resistant falciparum malaria. *The New England Journal of Medicine,* 344(4). Pp.299-302.

Winzeler EA, Manary MJ, 2014. Drug resistance genomic of the antimalarial drug artemisinin. Genome biologi, 15(544)

White N.J., 2004. Antimalarial drug resistance, *J. Clin Invest,* 113, pp.1084-1092

White NJ, Pongtavorpinyo W, Maude RJ, 2009. Hyperparasitemia and low dosing are an important source of anti malarial drug resistance. *Malar J*. 8. P253

WHO, 2003. *Assesment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria*, Geneva:WHO. The Institute

WHO, 2006. *Guidelines for the treatment of malaria*, Geneva :WHO. The Institute

WHO, 2011. *Global plan for artemisinin resistance containment*, Geneva :WHO. The Institute

WHO, 2014. *Global Malaria Programme : Status report on artemsinin resistance 2014. Geneva*. WHO. The Institute.

WHO, 2015. *Global Malaria Programme : Status report on artemsinin resistance 2015. Geneva*. WHO. The Institute.

WHO, 2015. *World Malaria Report 2014. Geneva*. WHO. The Institute.

Wright S, 1952. The theoritical variance within and among subdivision of a population that is in steady stage. *Genetrics*. 37, p312-321